There are 6.4 million doses earmarked for the U.S. for this month expected to cover one percent of the population.
The announcement came after revelations last week that the White House opted not to lock in an additional 100 million doses of Pfizer's vaccine for delivery in the second quarter of 2021.
Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said he was blown away by the fact that the coronavirus genome was first sequenced in January and now the country will have "a vaccine in somebody's arm in less than a year".
However, initial doses are scarce and rationed as the USA joins Britain and several other countries in scrambling to vaccinate as many people as possible ahead of a long, grim winter.
At a news conference, FDA Commissioner Stephen Hahn said he would "absolutely" get the vaccine as soon as he is eligible.
Perna said that his group did not pre-position the vaccine for distribution, not wanting to presume that the FDA would issue its authorization before it did so.
The first shipment of the Pfizer/BioNTech vaccine will be roughly 2.9 million doses.
However, residents of long-term care facilities, for example, are already in contact with workers and they can be vaccinated, even if they've been exposed.
The FDA said their analysis confirmed that the vaccine was safe and provided 95 per cent protection.
Hahn denied this had occurred, telling reporters: 'The representations in the press that I was threatened to be fired if we didn't get it done by a certain date is inaccurate'. Perna said health authorities would decide. The doses are meant to prepare for emergencies, like vaccine spoilage.Читайте также: Hayden Christensen Will Return As Darth Vader In ‘Obi-Wan Kenobi’ Series
Operation Warp Speed has previously said that states will not incur abnormally large expenses in administering the vaccine. The company has developed dry ice containers to address the issue.
The FDA, which hosted the briefing, balked at questions regarding whether someone who is pregnant should receive the vaccine.
Safety monitoring of COVID-19 vaccines was as robust as for other vaccines and the EMA regularly spoke with manufacturers about safety studies and whom to include in clinical trials, the agency also assured.
"It will be something that providers will need to consider on an individual basis for patients".
And a third vaccine developed with US government assistance, from Sanofi and GlaxoSmithKline, won't be ready until late next year, the companies said Friday - blaming a preliminary study that found an insufficient immune response in older adults.
Marks suggested one of the benefits of vaccinating teens would be tamping down on their ability to spread the virus.
In Canada, all vaccines carry a warning about the risk of serious allergic reactions, including anaphylaxis. But he added that the FDA will continue to monitor for further allergic reactions and "may have to modify things as we move forward".
It also has an agreement with Moderna for enough vaccine doses to cover 25 million people starting in the first half of next year.
The vaccine is administered as a series of two doses, three weeks apart. "That it seems pretty foolhardy to just conjecture that one dose might be okay without knowing". "We spent so much time carefully reviewing the data and basing our decisions on science, right?"При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог